Replies to post #97424 on Biotech Values

[genisi]

Exactly. I wouldn't underestimate Victoza in taking a big chunk of the GLP-1 market and certainly wouldn't think of it as a monopoly for bydureon. Will patients prefer the once-weekly formulation over a better pen delivery is yet to be seen.